IL133535A0 - Method for inhibiting bone resorption - Google Patents

Method for inhibiting bone resorption

Info

Publication number
IL133535A0
IL133535A0 IL13353598A IL13353598A IL133535A0 IL 133535 A0 IL133535 A0 IL 133535A0 IL 13353598 A IL13353598 A IL 13353598A IL 13353598 A IL13353598 A IL 13353598A IL 133535 A0 IL133535 A0 IL 133535A0
Authority
IL
Israel
Prior art keywords
bone resorption
disclosed
inhibiting bone
methods
etridronate
Prior art date
Application number
IL13353598A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL133535(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Priority to IL14121898A priority Critical patent/IL141218A0/xx
Priority to IL15310998A priority patent/IL153109A/en
Priority to IL14326498A priority patent/IL143264A0/xx
Publication of IL133535A0 publication Critical patent/IL133535A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
IL13353598A 1997-07-22 1998-07-17 Method for inhibiting bone resorption IL133535A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL14121898A IL141218A0 (en) 1997-07-22 1998-07-17 Alendronic acid, pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament or for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any of thereof, all for inhibiting bone resorption
IL15310998A IL153109A (en) 1997-07-22 1998-07-17 An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture
IL14326498A IL143264A0 (en) 1997-07-22 1998-07-17 A combination of a histamine h2 receptor blocker or a proton pump inhibitor and a bisphosphonate or pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament, for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any thereof, all for inhibiting bone resorption

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption
PCT/US1998/014796 WO1999004773A2 (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Publications (1)

Publication Number Publication Date
IL133535A0 true IL133535A0 (en) 2001-04-30

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13353598A IL133535A0 (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Country Status (31)

Country Link
EP (5) EP0998292B1 (cg-RX-API-DMAC7.html)
JP (2) JP3479780B2 (cg-RX-API-DMAC7.html)
KR (3) KR100391732B1 (cg-RX-API-DMAC7.html)
CN (3) CN1299689C (cg-RX-API-DMAC7.html)
AT (2) ATE357921T1 (cg-RX-API-DMAC7.html)
AU (1) AU8493698A (cg-RX-API-DMAC7.html)
BG (1) BG66282B1 (cg-RX-API-DMAC7.html)
BR (1) BR9810779A (cg-RX-API-DMAC7.html)
CA (1) CA2294595C (cg-RX-API-DMAC7.html)
CY (2) CY1107535T1 (cg-RX-API-DMAC7.html)
DE (6) DE01201911T1 (cg-RX-API-DMAC7.html)
DK (2) DK0998292T3 (cg-RX-API-DMAC7.html)
EA (1) EA004544B2 (cg-RX-API-DMAC7.html)
EE (1) EE05603B1 (cg-RX-API-DMAC7.html)
ES (3) ES2253136T1 (cg-RX-API-DMAC7.html)
HK (4) HK1042230A1 (cg-RX-API-DMAC7.html)
ID (1) ID24096A (cg-RX-API-DMAC7.html)
IL (1) IL133535A0 (cg-RX-API-DMAC7.html)
IS (3) IS5315A (cg-RX-API-DMAC7.html)
LU (2) LU91222I2 (cg-RX-API-DMAC7.html)
NL (2) NL300223I1 (cg-RX-API-DMAC7.html)
NO (1) NO20000323L (cg-RX-API-DMAC7.html)
NZ (1) NZ501807A (cg-RX-API-DMAC7.html)
PL (1) PL195272B1 (cg-RX-API-DMAC7.html)
PT (2) PT998292E (cg-RX-API-DMAC7.html)
SG (2) SG109478A1 (cg-RX-API-DMAC7.html)
SI (1) SI0998292T1 (cg-RX-API-DMAC7.html)
SK (1) SK932000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200000145T2 (cg-RX-API-DMAC7.html)
UY (1) UY25950A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999004773A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356294C (en) 1998-12-25 2007-06-05 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical compositions for treating bone lesions in multiple myeloma
IL146520A0 (en) * 1999-05-21 2002-07-25 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
WO2001005403A1 (en) * 1999-07-19 2001-01-25 Toray Industries, Inc. Drugs for periodontal diseases
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
CA2405360A1 (en) * 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
EP1296689B3 (en) 2000-06-20 2013-02-13 Novartis AG Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
ES2268086T3 (es) * 2001-05-02 2007-03-16 Novartis Ag Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
PL371346A1 (en) 2002-05-10 2005-06-13 F.Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
BRPI0615770A2 (pt) * 2005-09-16 2011-05-24 Selamine Ltd formulação de bisfosfonato
PT2648702T (pt) * 2010-12-06 2019-03-29 Effrx Pharmaceuticals Sa Formulações de bifosfonatos efervescentes estáveis com caracteristicas de rápida solubilização
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
EP0521388B1 (de) * 1991-07-01 1995-05-10 Gerhard Dr. Gergely Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
ES2149781T3 (es) * 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1994000129A1 (en) * 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Use of phosphonates for the treatment of osteoporosis
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
CA2254060C (en) * 1996-05-17 2007-05-01 Merck & Co., Inc. Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
EA004544B2 (ru) 2006-12-29
EE200000040A (et) 2000-10-16
NZ501807A (en) 2003-02-28
IS7231A (is) 2004-04-21
DK1175904T3 (da) 2007-05-07
LU91364I2 (fr) 2007-11-12
DK0998292T3 (da) 2002-05-13
DE122007000063I1 (de) 2007-12-20
AU8493698A (en) 1999-02-16
HK1024166A1 (en) 2000-10-05
NO20000323L (no) 2000-03-20
PL338635A1 (en) 2000-11-06
CY2007022I1 (el) 2012-01-25
KR20010022110A (ko) 2001-03-15
HK1042230A1 (en) 2002-08-09
PT1175904E (pt) 2007-04-30
EP1175904A2 (en) 2002-01-30
EP1175903A2 (en) 2002-01-30
CN1602880A (zh) 2005-04-06
CY1107535T1 (el) 2012-01-25
EP1175903A3 (en) 2002-12-18
KR100391732B1 (ko) 2003-07-16
ATE209037T1 (de) 2001-12-15
NL300223I1 (nl) 2006-04-03
SG109478A1 (en) 2005-03-30
LU91222I2 (fr) 2006-04-18
EP1175904B1 (en) 2007-03-28
EP1175904A3 (en) 2002-12-18
EP0998292B1 (en) 2001-11-21
CA2294595A1 (en) 1999-02-04
CN1166365C (zh) 2004-09-15
JP2005068010A (ja) 2005-03-17
IS7230A (is) 2004-04-21
PT998292E (pt) 2002-04-29
SI0998292T1 (en) 2002-04-30
HK1040495A1 (en) 2002-06-14
DE69837450T2 (de) 2007-08-23
EP1132088A2 (en) 2001-09-12
ES2269014T3 (es) 2007-05-01
BR9810779A (pt) 2000-07-25
EA200000151A1 (ru) 2000-10-30
TR200000145T2 (tr) 2000-05-22
JP2002502433A (ja) 2002-01-22
DE122006000009I1 (de) 2006-06-14
EP1175904B8 (en) 2007-05-09
NL300292I1 (nl) 2007-11-01
ES2253136T1 (es) 2006-06-01
WO1999004773A2 (en) 1999-02-04
ES2269014T1 (es) 2007-04-01
EP1132088A3 (en) 2002-04-24
KR20030097610A (ko) 2003-12-31
EE05603B1 (et) 2012-12-17
PL195272B1 (pl) 2007-08-31
WO1999004773A9 (en) 1999-10-28
CN1602879A (zh) 2005-04-06
BG66282B1 (bg) 2013-01-31
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
UY25950A1 (es) 2000-09-29
DE69803291T2 (de) 2002-08-08
CY2007022I2 (el) 2012-01-25
ES2164447T3 (es) 2002-02-16
CA2294595C (en) 2001-08-21
WO1999004773A3 (en) 1999-04-15
DE69837450D1 (de) 2007-05-10
BG104093A (en) 2000-10-31
JP3479780B2 (ja) 2003-12-15
DE01201911T1 (de) 2007-10-18
EA004544B1 (ru) 2004-06-24
HK1042232A1 (en) 2002-08-09
EP0998292A2 (en) 2000-05-10
DE69803291D1 (de) 2002-02-21
CN1265035A (zh) 2000-08-30
HK1040494A1 (en) 2002-06-14
SK932000A3 (en) 2000-09-12
EP1151752A2 (en) 2001-11-07
ATE357921T1 (de) 2007-04-15
DE01201913T1 (de) 2007-02-08
KR20030097611A (ko) 2003-12-31
IS5315A (is) 1999-12-21
EP1151752A3 (en) 2002-12-18
ID24096A (id) 2000-07-06
CN1299689C (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
LU91364I2 (fr) Alendronate de sodium /colécalciférol
NZ272608A (en) Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
HRP20020594B1 (en) Pharmaceutical parenteral composition containing a biphosphonate
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
YU1800A (sh) Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju
BR9609477A (pt) Composto composição farmacêutica e processos para preparação de tiludronato dissódico e para obtenção de uma composição farmacêutica
PE120399A1 (es) Composiciones que inhiben la resorcion osea
TWI226833B (en) Pharmaceutical composition for inhibiting bone resorption
CA2171111A1 (en) Inhibition of urinary calculi growth